ArticleGland surgery2026
A simple four-variable nomogram integrating age, ACR-TIRADS, BRAF V600E and Bethesda cytology for predicting occult central lymph node metastasis in papillary thyroid microcarcinoma: a preoperative risk-stratification tool.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Predicting occult central lymph node metastasis (CLNM) in papillary thyroid microcarcinoma (PTMC) is important for individualized surgical planning and risk-stratified decision-making, particularly in younger patients. This study aimed to develop and internally validate a simple four-variable nomogram integrating age, American College of Radiology Thyroid Imaging Reporting and Data System (ACR-TIRADS), BRAF V600E status, and Bethesda cytology for preoperative prediction of occult CLNM in PTMC. Methods: We retrospectively analyzed 130 PTMC patients (≤10 mm on pre-operative ultrasound) who underwent thyroidectomy with central lymph node dissection (CLND) at a single Chinese tertiary center (March 2020-December 2022). A four-variable logistic-regression nomogram (Model E) was developed integrating age, ACR-TIRADS category, BRAF V600E mutation status (from fine-needle aspiration), and Bethesda cytological classification. Internal validation used 5-fold stratified cross-validation. Calibration was assessed by the Hosmer-Lemeshow test and calibration curves; clinical utility by decision curve analysis (DCA). Results: CLNM was confirmed in 73/130 patients (56.2%). The 5-fold cross-validated area under the receiver operating characteristic curve (AUC) was 0.686, with acceptable calibration (Brier score 0.215; Hosmer-Lemeshow P=0.43). DCA demonstrated positive net clinical benefit across threshold probabilities of 0.31-0.95. Pre-specified but exploratory subgroup analyses suggested higher apparent discrimination in patients younger than 45 years (n=60; bootstrap median AUC 0.760, 95% CI: 0.574-0.888) and in BRAF wild-type cases (n=35; 0.864, 95% CI: 0.705-0.977), although CIs were wide and overlapping. In this PTMC cohort, BRAF V600E was not independently associated with CLNM; an inverse point estimate was observed but did not reach statistical significance and should be regarded as exploratory. Conclusions: This simple, four-variable nomogram provides clinically useful pre-operative CLNM risk assessment in PTMC, particularly in younger and BRAF wild-type patients-subgroups in which preoperative risk stratification is most challenging. External multi-center validation is the necessary next step.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.